Crispr Therapeutics AG (CRSP)vsInsmed Inc (INSM)
CRSP
Crispr Therapeutics AG
$47.09
+1.42%
HEALTHCARE · Cap: $4.46B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 17177% more annual revenue ($606.42M vs $3.51M). CRSP leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CRSP
Avoid27
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -30.2% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CRSP
The strongest argument for CRSP centers on Altman Z-Score, Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CRSP
The primary concerns for CRSP are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CRSP profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
CRSP carries more volatility with a beta of 1.74 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
CRSP generates stronger free cash flow (-93M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Crispr Therapeutics AG
HEALTHCARE · BIOTECHNOLOGY · USA
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?